Israel’s BiolineRX in conjunction with Ben Gurion University, Hadassah Medical Center and Novartis has developed a novel treatment BL-1220 that can restore liver function in patients with liver disease and injury. http://www.biolinerx.com/default.asp?pageid=16&itemid=469

Hadasit, the Hadassah Medical Organization’s technology transfer company, and Israel’s BioLineRx are to develop a treatment BL-1210 for non-alcoholic steatohepatitis (NASH) or fatty liver disease.  It modulates the immune system to reduce scarring that leads to cirrhosis.  There is currently … Continue reading →

Latest reports of Phase II trials of BL-8040 from Israel’s Bioline Rx (see Nov newsletter), show that 38% of patients with acute myeloid leukemia, went into complete remission after just two cycles of the treatment.  All these patients had previously … Continue reading →

Israel’s BiolineRX is to perform a Phase II clinical test combining BiolineRX’s BL-8040 with Merck’s KEYTRUDA anti-PD-1 therapy in the treatment of patients with metastatic pancreatic adenocarcinoma. http://www.globes.co.il/en/article-biolinerx-merck-to-collaborate-on-pancreatic-cancer-treatment-1001094833

Israel’s BiolineRx has reported positive results from Phase II trials of its BL-8040 treatment in relapsed or refractory acute myeloid leukemia (r/r AML). It had a triple positive effect on the leukemic cells only two days after a single cycle … Continue reading →

Professor Ofer Mandelboim of the Hebrew University in Jerusalem has won the 2015 Kaye Innovation for discovering that blocking the NKp46 receptor on Natural Killer cells delays or prevents the onset of Type 1 (Juvenile) Diabetes. Israel’s BioLineRX developed BL-9020 … Continue reading →

Back in Feb 2012 I reported good pre-clinical trials of Israeli biotech BioLineRX’s BL-7010 co-polymer for the treatment of celiac disease, for which there is currently no cure or formal treatment. BioLineRX has now announced successful final results from its … Continue reading →

(Thanks to Atid-EDI) Israel’s BioLineRX announced that its BL-8040 treatment for Chronic Myeloid Leukemia (CML) stopped growth of cancer cells in-vitro and caused them to self-destruct. It also reversed any protection given to the CML cancer cells from a bone … Continue reading →

The United States FDA has granted orphan drug status to Israeli biotech BioLineRX’s BL-8040 treatment of acute myeloid leukemia. Because there are limited alternatives, BioLineRX will now receive US Federal support, financial assistance and market exclusivity. http://www.globes.co.il/serveen/globes/docview.asp?did=1000878182&fid=1725

Israel’s BioLineRx has licensed its BL-8030 oral treatment for the Hepatitis C virus (HCV) to China’s Jiangsu Chia-tai Tianqing. Approximately 43 million Chinese suffer from Hepatitis C – a chronic and debilitating disease. http://www.globes.co.il/serveen/globes/docview.asp?did=1000851299&fid=1725